Patients with metastatic EGFR-mutant NSCLC inevitably have disease progression while on TKI therapy. Co-occurring tumor suppressor gene (TSG) alterations have been associated with poor outcomes, however, detailed analyses of their impact on patient outcomes are limited. Patients with EGFR-mutant NSCLC treated with EGFR-TKIs who had tumor genomic profiling were included. Alterations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1 and PTEN) were used to stratify the cohort into three subgroups: patients with tumors harboring a TP53 mutation plus a mutation in ≥1 additional TSG (TP53mut/TSGmut), a TP53 mutation without additional TSG mutations (TP53mut/TSGwt), and TP53wt. Patient characteristics and clinical outcomes were assessed in two independent cohorts. 101 patients from the Yale Cancer Center and 182 patients from the AACR Project GENIE database were included. In the Yale cohort, TP53 mutations were identified in 65 (64%) cases (of which 23 were TP53mut/TSGmut and 42 were TP53mut/TSGwt). Although the presence of a TP53 mutation was associated with worse outcomes, the additional TSG alteration in TP53mut tumors identified a subset of patients associated with particularly aggressive disease and inferior clinical outcome in both the Yale and the GENIE cohort. Specifically, in the Yale cohort for patients receiving first-line TKI, those with TP53mut/TSGmut tumors had shorter PFS and OS than TP53mut/TSGwt (PFS: HR 2.03, CI 1.12 - 3.69, P<0.01, OS: HR 1.58, CI 0.82 - 3.04, P=0.12) or TP53wt cases (PFS: HR 2.4, CI 1.28 - 4.47, P<0.001, OS: HR 2.54, CI 1.21 - 5.34, P<0.005). Inferior outcomes in TP53mut/TSGmut tumors were also seen in patients receiving osimertinib as second-line therapy. Patients with TP53mut/TSGmut tumors represent a patient subgroup characterized by an aggressive disease phenotype and inferior outcomes on EGFR-TKIs. This information is important for understanding the biologic underpinnings of differential outcomes with TKI treatment and has implications for identifying patients for additional therapeutic interventions beyond osimertinib monotherapy.